Biological and clinical significance of PARP1 protein expression in breast cancer

Breast Cancer Research and Treatment

Volumn 149, Issue 2, 2015, Pages 353-362

  Green, Andrew R ^a   Caracappa, Daniela ^a,b,c   Benhasouna, Ahmed A ^a   Alshareeda, Alaa ^a   Nolan, Christopher C ^a   Macmillan, R Douglas ^b   Madhusudan, Srinivasan ^a   Ellis, Ian O ^a,b   Rakha, Emad A ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Biology; BRCA1; Breast cancer; Clinical significance; DNA repair gene defects; PARP1

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 1; KU ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN PIAS GAMMA; RAD51 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BREAST CANCER; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; UPREGULATION; ADULT; BREAST TUMOR; CANCER GRADING; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN;

EID: 84925541094     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3230-1     Document Type: Article

References (34)

1. Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481(7381):287–294
2. Burkle A (2001) Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability. Cancer Lett 163(1):1–5
3. Ame JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. BioEssays 26(8):882–893
4. Krishnakumar R, Kraus WL (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39(1):8–24
5. Schreiber V et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7(7):517–528
6. Sultana R et al (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 131(10):2433–2444
7. Cerbinskaite A et al (2012) Defective homologous recombination in human cancers. Cancer Treat Rev 38(2):89–100
8. Orlando L et al (2012) Poly(ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opin Ther Targets 16(Suppl 2):S83–S89
9. Tutt A et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244
10. Germain M et al (1999) Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 274(40):28379–28384
11. Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54(3):375–429
12. Ossovskaya V et al (2010) Upregulation of poly(ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1(8):812–821
13. Quiles-Perez R et al (2010) Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 51(1):255–266
14. Nosho K et al (2006) Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 42(14):2374–2381
15. Kononen J et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847
16. McCarty KS Jr, McCarty KS Sr (1984) Histochemical approaches to steroid receptor analyses. Semin Diagn Pathol 1(4):297–308
17. Aleskandarany MA et al (2011) Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res 14(1):R3
18. Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310
19. Rakha EA et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32
20. Domagala P et al (2011) PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 127(3):861–869
21. Gan A et al (2013) Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol 44(8):1638–1647
22. Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921
23. McCabe N et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115
24. Plummer R (2010) Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 13(4):218
25. Bryant HE et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917
26. Wang J et al (2008) Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter. J Biol Chem 283(52):36249–36256
27. Alli E et al (2009) Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69(8):3589–3596
28. Anders CK et al (2010) Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res 16(19):4702–4710
29. McCool K, Miyamoto S (2009) A PAR-SUMOnious mechanism of NEMO activation. Mol Cell 36(3):349–350
30. Idogawa M et al (2007) Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 67(3):911–918
31. Cheng Q et al (2011) Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res 39(22):9605–9619
32. Yu SW et al (2006) Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103(48):18314–18319
33. Erener S et al (2012) Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes. Mol Cell 46(2):200–211
34. Rakha EA et al (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50(4):434–438